Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Schizophrenia Market to Gain Momentum During the Forecast Period (2026-2036), with Growing Pipeline of Novel... (PR Newswire) +++ MEDINCELL Aktie -5,02%

ABBVIE Aktie

 >ABBVIE Aktienkurs 
244 EUR    +3.0%    (TradegateBSX)
Ask: 243.3 EUR / 410 Stück
Bid: 242.7 EUR / 420 Stück
Tagesumsatz: 3434 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
ABBVIE Aktie über LYNX handeln
>ABBVIE Performance
1 Woche: +1,7%
1 Monat: +7,3%
3 Monate: +6,1%
6 Monate: +31,1%
1 Jahr: +20,6%
laufendes Jahr: +20,5%
>ABBVIE Aktie
Name:  ABBVIE INC. DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US00287Y1091 / A1J84E
Symbol/ Ticker:  4AB (Frankfurt) / ABBV (NYSE)
Kürzel:  FRA:4AB, ETR:4AB, 4AB:GR, NYSE:ABBV
Index:  S&P500
Profil:  AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and commercializes medicines and therapies for complex and serious diseases. AbbVie focuses on major therapeutic areas including immunology, oncology, neuroscience, eye ca..
>Volltext..
Marktkapitalisierung:  417186.66 Mio. EUR
Unternehmenswert:  473294.63 Mio. EUR
Umsatz:  57196.16 Mio. EUR
EBITDA:  26577.12 Mio. EUR
Nettogewinn:  5568.07 Mio. EUR
Gewinn je Aktie:  3.14 EUR
Schulden:  62913.46 Mio. EUR
Liquide Mittel:  5835.45 Mio. EUR
Operativer Cashflow:  17328.7 Mio. EUR
Bargeldquote:  0.16
Umsatzwachstum:  13.86%
Gewinnwachstum:  73.66%
Dividende je Aktie:  5.88 EUR
Dividendenrendite:  2.57%
Dividendenschätzung:  2.63%
Div. Historie:  15.07.26 - 1.5115011€
15.04.26 - 1.467559€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  ABBVIE
Letzte Datenerhebung:  07.10.26
>ABBVIE Kennzahlen
Aktien/ Unternehmen:
Aktien: 1767.12 Mio. St.
Frei handelbar: 99.9%
Rückkaufquote: 0.3%
Mitarbeiter: 57000
Umsatz/Mitarb.: 0.95 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 5.98%
Bewertung:
KGV: 76.46
KGV lG: 18.93
KUV: 7.25
KBV: -
PEG-Ratio: 1.09
EV/EBITDA: 17.81
Rentabilität:
Bruttomarge: 71.42%
Gewinnmarge: 9.74%
Operative Marge: 34.18%
Managementeffizenz:
Gesamtkaprendite: 4.6%
Eigenkaprendite: -
 >ABBVIE Anleihen 
>ABBVIE Peer Group
Gesundheit, Augenmedizin/ Sehhilfen, Neurologische Erkrankungen/ Schlaganfälle, Onkologie/ Krebs- Behandlung, Autoimmunerkrankungen
 
07.10.26 - 15:24
AbbVie′s Telisotuzumab Adizutecan Secures Dual FDA Breakthrough Therapy Designations (AFX)
 
WASHINGTON (dpa-AFX) - Wednesday, AbbVie Inc. (ABBV) announced that the U.S. Food and Drug Administration has granted two Breakthrough Therapy Designations for telisotuzumab adizutecan or Temab-A ......
07.10.26 - 14:33
AbbVie′s Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC (PR Newswire)
 
Temab-A is an investigational, next-generation, c-Met-directed antibody-drug conjugate (ADC) with a novel topoisomerase 1 inhibitor (Top1i) being studied in advanced solid tumors including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) These designations represent the......
06.10.26 - 19:48
HSBC Thinks AbbVie Can Climb to $315. Here′s the Bull Case in Plain English. (Fool)
 
A recent analyst lays out a concrete bull case, but it is not the only path to higher prices for AbbVie....
06.10.26 - 16:45
Wall Street Analysts See AbbVie (ABBV) as a Buy: Should You Invest? (Zacks)
 
The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?...
06.10.26 - 16:33
Parkinson′s Disease Market Poised for Expansion During the Forecast Period (2026-2036) Amid JUVMO Approval and Emerging Therapeutic Innovations | DelveInsight (PR Newswire)
 
The Parkinson's disease market is expected to grow steadily, driven by the recent approval of AbbVie's JUVMO along with the rising prevalence of the disease, particularly among the aging population. Increasing disease awareness, improved diagnosis, and advances in symptomatic and......
06.10.26 - 16:24
Should You Buy AbbVie Stock Before Oct. 30? (Fool)
 
The healthcare company will release its third-quarter numbers later this month....
06.10.26 - 14:48
Genmab jumps after positive trial of AbbVie-partnered lymphoma drug (ShareCast)
 
Shares in Danish biotech group Genmab jumped to a three-year high on Tuesday after a late-stage trial of its lymphoma treatment developed with AbbVie delivered better outcomes than the current standard therapy....
06.10.26 - 14:30
AbbVie Rewarded Patient Investors but Punished Those Who Bought on Good News (24/7 Wall St.)
 
AbbVie investors who bought on headline-grabbing drug approvals consistently trailed those who bought during fear and uncertainty. The calendar of milestones reveals a counterintuitive pattern about when good news becomes a trap....
06.10.26 - 09:36
Genmab-Aktie springt nach Studienerfolg bei Lymphom-Medikament mit AbbVie (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
06.10.26 - 09:36
Genmab jumps as its lymphoma drug combo with AbbVie cuts progression, death risk (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
06.10.26 - 07:42
AbbVie, Genmab′s Epcoritamab Plus R-CHOP Improves PFS In DLBCL (AFX)
 
WASHINGTON (dpa-AFX) - AbbVie (ABBV) and Genmab (GMAB) reported positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating epcoritamab plus R-CHOP in patients with newly diagnosed d......
06.10.26 - 01:00
Why AbbVie (ABBV) Outpaced the Stock Market Today (Zacks)
 
AbbVie (ABBV) closed at $265.85 in the latest trading session, marking a +1.15% move from the prior day....
05.10.26 - 23:09
AbbVie flags $216M IPR&D and milestones expense for Q3 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.10.26 - 21:48
Why I Think These Are the 2 Smartest Stocks to Buy With $5,000 in October (Fool)
 
AbbVie and Medtronic are both stable blue chip dividend plays in this choppy market....
05.10.26 - 21:45
Genmab, AbbVie data boosts Epkinly as first-line B-cell lymphoma treatment (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.10.26 - 21:00
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (PR Newswire)
 
EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed diffuse large B-cell lymphoma (DLBCL) patients Based on the......
03.10.26 - 20:42
AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
03.10.26 - 12:24
AbbVie Just Won FDA Approval for a Once-Daily Parkinson′s Pill. Here′s Why It Matters More Than You Think. (Fool)
 
Another potential blockbuster just joined AbbVie's drug portfolio....
02.10.26 - 17:30
Can ABBV′s New Parkinson′s Pill Strengthen Its Neuroscience Franchise? (Zacks)
 
AbbVie's FDA approval of Juvmo expands its Parkinson's portfolio, with a commercial launch targeted for October 2026....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Mann der Arbeit, aufgewacht und erkenne deine Macht. Alle Räder stehen still wenn dein starker Arm es will. - Georg Herwegh
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!